Journal article
Assessment of synthetic red cell therapy for extremely preterm ovine fetuses maintained on an artificial placenta life‐support platform
Artificial Organs, Vol.46(4), pp.653-665
2022
Abstract
Background
Artificial placenta therapy (APT) is an experimental care strategy for extremely preterm infants born at 21–24 weeks’ gestation. In our previous studies, blood taken from the maternal ewe was used as the basis of priming solutions for the artificial placenta circuit. However, the use of maternal blood as a priming solution is accompanied by several challenges. We explored the use of synthetic red cells (hemoglobin vesicles; HbV) as the basis of a priming solution for APT used to manage extremely early preterm ovine fetuses.
Methods
Six ewes with singleton pregnancies at 95 d gestation (term = 150 d) were adapted to APT and maintained with constant monitoring of key vital parameters. The target maintenance period was 72 h in duration. A synthetic red cell solution consisting of HbV, sheep albumin and electrolytes was used as priming solutions for the APT circuit. Fetuses were evaluated on gross appearance, physiological parameters and bleeding after euthanasia.
Results
Two out of six APT fetuses were successfully maintained for the targeted 72 h experimental period with controllable anemia (>10 g/dl) and methemoglobinemia (<10%) using an infusion of blood transfusion and nitroglycerin delivered >1 h after APT commencement, a sufficient period of time to cross-match blood products and screen for viral agents of concern.
Conclusions
Extremely preterm sheep fetuses were maintained for a period of up to 72 h using APT in combination with circuit priming using a synthetic red cell (HbV) preparation. Although significant further refinements are required, these findings demonstrated the potential clinical utility of synthetic blood products in the eventual clinical translation of artificial placenta technology to support extremely preterm infants.
Details
- Title
- Assessment of synthetic red cell therapy for extremely preterm ovine fetuses maintained on an artificial placenta life‐support platform
- Authors/Creators
- H. Usuda (Author/Creator) - The University of Western AustraliaM. Saito (Author/Creator) - The University of Western AustraliaH. Ikeda (Author/Creator) - Tohoku University HospitalS. Sato (Author/Creator) - Tohoku University HospitalY. Kumagai (Author/Creator) - Tohoku University HospitalY. Saito (Author/Creator) - Tohoku University HospitalS. Kawamura (Author/Creator) - Nipro (Japan)T. Hanita (Author/Creator) - Tohoku University HospitalH. Sakai (Author/Creator) - Nara Medical UniversityS. Kure (Author/Creator) - Tohoku University HospitalN. Yaegashi (Author/Creator) - Tohoku University HospitalJ.P. Newnham (Author/Creator) - The University of Western AustraliaM.W. Kemp (Author/Creator) - The University of Western AustraliaS. Watanabe (Author/Creator) - Tohoku University Hospital
- Publication Details
- Artificial Organs, Vol.46(4), pp.653-665
- Publisher
- Wiley
- Identifiers
- 991005541068407891
- Murdoch Affiliation
- School of Veterinary and Life Sciences
- Language
- English
- Resource Type
- Journal article
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: InCites
Metrics
32 Record Views
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
- Collaboration types
- Industry collaboration
- Domestic collaboration
- International collaboration
- Citation topics
- 1 Clinical & Life Sciences
- 1.225 Hematologic Diseases
- 1.225.1098 Hemoglobin Function
- Web Of Science research areas
- Engineering, Biomedical
- Transplantation
- ESI research areas
- Clinical Medicine